HMN 2025: How Weekly semaglutide improves blood sugar and weight in adults with kind 1 diabetes, medical trial finds

A brand new medical trial discovered that taking a well-liked diabetes and weight-loss drug as soon as weekly considerably improves blood sugar and results in substantial weight reduction in adults with kind 1 diabetes who use automated insulin supply methods.

The outcomes are printed today within the journal NEJM Evidence.

Semaglutide is a drugs that belongs to a category of medication generally known as glucagon-like peptide-1, or GLP-1, receptor agonists. Sold beneath the commerce names similar to Ozempic, Wegovy and Rybelsus, the drug was initially developed for the therapy of kind 2 diabetes, serving to to handle blood sugar ranges.

The 26-week, double-blind study concerned 72 members throughout 4 medical facilities, together with Oregon Health & Science University. Researchers discovered that 36% of sufferers taking semaglutide met all three key well being targets—improved blood glucose ranges, diminished time spent in low blood sugar and not less than 5% weight reduction—in comparison with none within the placebo group.

“Semaglutide helped extra folks attain their blood sugar and weight targets with out lowering blood sugar,” mentioned Andrew Ahmann, M.D., emeritus professor of medication at Oregon Health & Science University’s School of Medicine, and a co-author on the review.

Those on semaglutide misplaced a mean of about 18.5 kilos over six months within the study and noticed modest enhancements in common blood sugar ranges (A1C) and the period of time blood sugar stays in a wholesome vary, with no larger danger of harmful low blood sugar or severe problems like diabetic ketoacidosis.

While semaglutide is already permitted for kind 2 diabetes and weight problems, its use in kind 1 diabetes stays investigational. This is the primary randomized medical trial to point out that the treatment might also be efficient in kind 1 diabetes in sufferers already utilizing automated insulin supply.

Viral Shah, M.D., of the Indiana University School of Medicine, is senior creator on the review. In addition to Shah and Ahmann, different co-authors embrace Halis Akturk, M.D. and Janet Snell-Bergeon, Ph.D., of University of Colorado Anschutz Medical Campus, Davida Kruger, D.N.P., M.D., of Henry Ford Health, Anuj Bhargava, M.D., of Iowa Diabetes Research, Giorgos Bakoyannis, Ph.D., of Indiana University School of Medicine, and Laura Pyle, Ph.D., of the University of Washington.